(Total Views: 370)
Posted On: 03/08/2021 9:37:06 PM
Post# of 153933
Quote:
Sure would have been nice to conduct a larger trial. Perhaps this is why smaller biotechs have trouble getting over the finish line.
This exact statement is why I’ll probably never invest in a small pre-revenue biotech again. A BP would have run a trial last summer of 3000 patients and we would have full approval by now. A small biotech run ing on financial fumes cannot pull off a trial big enough for the math-obsessed BP-bias of the FDA.
(4)
(0)
